 | • レポートコード：MRC2312MG09761 • 出版社/出版日：Market Monitor Global / 2023年12月 • レポート形態：英文、PDF、79ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品 |
| Single User | ￥481,000 (USD3,250) | ▷ お問い合わせ |
| Enterprise User | ￥721,500 (USD4,875) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査レポートは次の情報を含め、世界のGIP-1受容体作動薬市場規模と予測を収録しています。・世界のGIP-1受容体作動薬市場：売上、2018年-2023年、2024年-2029年 ・世界のGIP-1受容体作動薬市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界のGIP-1受容体作動薬市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「短時間作用型GLP-1受容体作動薬」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 GIP-1受容体作動薬のグローバル主要企業は、GSK、 Novo Nordisk、 Eli Lilly and Company、 Baxter Pharmaceutical Solutions、 Sanofi、 AstraZeneca、 Shanghai Benemae Pharmaceutical Corporation、 Sinopep Allsino Bio Pharmaceutical、 Huadong Medicine、 HANSOH PHARMA、 3SBioなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、GIP-1受容体作動薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界のGIP-1受容体作動薬市場：タイプ別、2018年-2023年、2024年-2029年 世界のGIP-1受容体作動薬市場：タイプ別市場シェア、2022年 ・短時間作用型GLP-1受容体作動薬、長時間作用型GLP-1受容体作動薬 世界のGIP-1受容体作動薬市場：用途別、2018年-2023年、2024年-2029年 世界のGIP-1受容体作動薬市場：用途別市場シェア、2022年 ・型糖尿病患者、肥満患者、その他 世界のGIP-1受容体作動薬市場：地域・国別、2018年-2023年、2024年-2029年 世界のGIP-1受容体作動薬市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業におけるGIP-1受容体作動薬のグローバル売上、2018年-2023年 ・主要企業におけるGIP-1受容体作動薬のグローバル売上シェア、2022年 ・主要企業におけるGIP-1受容体作動薬のグローバル販売量、2018年-2023年 ・主要企業におけるGIP-1受容体作動薬のグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 GSK、 Novo Nordisk、 Eli Lilly and Company、 Baxter Pharmaceutical Solutions、 Sanofi、 AstraZeneca、 Shanghai Benemae Pharmaceutical Corporation、 Sinopep Allsino Bio Pharmaceutical、 Huadong Medicine、 HANSOH PHARMA、 3SBio ************************************************************* ・調査・分析レポートの概要 GIP-1受容体作動薬市場の定義 市場セグメント 世界のGIP-1受容体作動薬市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界のGIP-1受容体作動薬市場規模 世界のGIP-1受容体作動薬市場規模：2022年 VS 2029年 世界のGIP-1受容体作動薬市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでのGIP-1受容体作動薬の売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業のGIP-1受容体作動薬製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：短時間作用型GLP-1受容体作動薬、長時間作用型GLP-1受容体作動薬 GIP-1受容体作動薬のタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：型糖尿病患者、肥満患者、その他 GIP-1受容体作動薬の用途別グローバル売上・予測 ・地域別市場分析 地域別GIP-1受容体作動薬市場規模 2022年と2029年 地域別GIP-1受容体作動薬売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） GSK、 Novo Nordisk、 Eli Lilly and Company、 Baxter Pharmaceutical Solutions、 Sanofi、 AstraZeneca、 Shanghai Benemae Pharmaceutical Corporation、 Sinopep Allsino Bio Pharmaceutical、 Huadong Medicine、 HANSOH PHARMA、 3SBio ... |
This research report provides a comprehensive analysis of the GIP-1 Receptor Agonist market, focusing on the current trends, market dynamics, and future prospects. The report explores the global GIP-1 Receptor Agonist market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of GIP-1 Receptor Agonist, challenges faced by the industry, and potential opportunities for market players.
The global GIP-1 Receptor Agonist market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The GIP-1 Receptor Agonist market presents opportunities for various stakeholders, including Type 2 Diabetics, Obese Patients. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in GIP-1 Receptor Agonist market. Additionally, the growing consumer demand present avenues for market expansion.
The global GIP-1 Receptor Agonist market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Key Features:
The research report on the GIP-1 Receptor Agonist market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the GIP-1 Receptor Agonist market.
Market Overview: The report provides a comprehensive overview of the GIP-1 Receptor Agonist market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Short-acting GLP-1 Receptor Agonist, Long-acting GLP-1 Receptor Agonist), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the GIP-1 Receptor Agonist market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the GIP-1 Receptor Agonist market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the GIP-1 Receptor Agonist market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the GIP-1 Receptor Agonist market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the GIP-1 Receptor Agonist market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the GIP-1 Receptor Agonist market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for GIP-1 Receptor Agonist, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the GIP-1 Receptor Agonist market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
GIP-1 Receptor Agonist market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
Short-acting GLP-1 Receptor Agonist
Long-acting GLP-1 Receptor Agonist
Market segment by Application
Type 2 Diabetics
Obese Patients
Others
Global GIP-1 Receptor Agonist Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
GSK
Novo Nordisk
Eli Lilly and Company
Baxter Pharmaceutical Solutions
Sanofi
AstraZeneca
Shanghai Benemae Pharmaceutical Corporation
Sinopep Allsino Bio Pharmaceutical
Huadong Medicine
HANSOH PHARMA
3SBio
Outline of Major Chapters:
Chapter 1: Introduces the definition of GIP-1 Receptor Agonist, market overview.
Chapter 2: Global GIP-1 Receptor Agonist market size in revenue and volume.
Chapter 3: Detailed analysis of GIP-1 Receptor Agonist manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of GIP-1 Receptor Agonist in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global GIP-1 Receptor Agonist capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 GIP-1 Receptor Agonist Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global GIP-1 Receptor Agonist Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global GIP-1 Receptor Agonist Overall Market Size
2.1 Global GIP-1 Receptor Agonist Market Size: 2022 VS 2029
2.2 Global GIP-1 Receptor Agonist Revenue, Prospects & Forecasts: 2018-2029
2.3 Global GIP-1 Receptor Agonist Sales: 2018-2029
3 Company Landscape
3.1 Top GIP-1 Receptor Agonist Players in Global Market
3.2 Top Global GIP-1 Receptor Agonist Companies Ranked by Revenue
3.3 Global GIP-1 Receptor Agonist Revenue by Companies
3.4 Global GIP-1 Receptor Agonist Sales by Companies
3.5 Global GIP-1 Receptor Agonist Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 GIP-1 Receptor Agonist Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers GIP-1 Receptor Agonist Product Type
3.8 Tier 1, Tier 2 and Tier 3 GIP-1 Receptor Agonist Players in Global Market
3.8.1 List of Global Tier 1 GIP-1 Receptor Agonist Companies
3.8.2 List of Global Tier 2 and Tier 3 GIP-1 Receptor Agonist Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global GIP-1 Receptor Agonist Market Size Markets, 2022 & 2029
4.1.2 Short-acting GLP-1 Receptor Agonist
4.1.3 Long-acting GLP-1 Receptor Agonist
4.2 By Type – Global GIP-1 Receptor Agonist Revenue & Forecasts
4.2.1 By Type – Global GIP-1 Receptor Agonist Revenue, 2018-2023
4.2.2 By Type – Global GIP-1 Receptor Agonist Revenue, 2024-2029
4.2.3 By Type – Global GIP-1 Receptor Agonist Revenue Market Share, 2018-2029
4.3 By Type – Global GIP-1 Receptor Agonist Sales & Forecasts
4.3.1 By Type – Global GIP-1 Receptor Agonist Sales, 2018-2023
4.3.2 By Type – Global GIP-1 Receptor Agonist Sales, 2024-2029
4.3.3 By Type – Global GIP-1 Receptor Agonist Sales Market Share, 2018-2029
4.4 By Type – Global GIP-1 Receptor Agonist Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global GIP-1 Receptor Agonist Market Size, 2022 & 2029
5.1.2 Type 2 Diabetics
5.1.3 Obese Patients
5.1.4 Others
5.2 By Application – Global GIP-1 Receptor Agonist Revenue & Forecasts
5.2.1 By Application – Global GIP-1 Receptor Agonist Revenue, 2018-2023
5.2.2 By Application – Global GIP-1 Receptor Agonist Revenue, 2024-2029
5.2.3 By Application – Global GIP-1 Receptor Agonist Revenue Market Share, 2018-2029
5.3 By Application – Global GIP-1 Receptor Agonist Sales & Forecasts
5.3.1 By Application – Global GIP-1 Receptor Agonist Sales, 2018-2023
5.3.2 By Application – Global GIP-1 Receptor Agonist Sales, 2024-2029
5.3.3 By Application – Global GIP-1 Receptor Agonist Sales Market Share, 2018-2029
5.4 By Application – Global GIP-1 Receptor Agonist Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global GIP-1 Receptor Agonist Market Size, 2022 & 2029
6.2 By Region – Global GIP-1 Receptor Agonist Revenue & Forecasts
6.2.1 By Region – Global GIP-1 Receptor Agonist Revenue, 2018-2023
6.2.2 By Region – Global GIP-1 Receptor Agonist Revenue, 2024-2029
6.2.3 By Region – Global GIP-1 Receptor Agonist Revenue Market Share, 2018-2029
6.3 By Region – Global GIP-1 Receptor Agonist Sales & Forecasts
6.3.1 By Region – Global GIP-1 Receptor Agonist Sales, 2018-2023
6.3.2 By Region – Global GIP-1 Receptor Agonist Sales, 2024-2029
6.3.3 By Region – Global GIP-1 Receptor Agonist Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America GIP-1 Receptor Agonist Revenue, 2018-2029
6.4.2 By Country – North America GIP-1 Receptor Agonist Sales, 2018-2029
6.4.3 US GIP-1 Receptor Agonist Market Size, 2018-2029
6.4.4 Canada GIP-1 Receptor Agonist Market Size, 2018-2029
6.4.5 Mexico GIP-1 Receptor Agonist Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe GIP-1 Receptor Agonist Revenue, 2018-2029
6.5.2 By Country – Europe GIP-1 Receptor Agonist Sales, 2018-2029
6.5.3 Germany GIP-1 Receptor Agonist Market Size, 2018-2029
6.5.4 France GIP-1 Receptor Agonist Market Size, 2018-2029
6.5.5 U.K. GIP-1 Receptor Agonist Market Size, 2018-2029
6.5.6 Italy GIP-1 Receptor Agonist Market Size, 2018-2029
6.5.7 Russia GIP-1 Receptor Agonist Market Size, 2018-2029
6.5.8 Nordic Countries GIP-1 Receptor Agonist Market Size, 2018-2029
6.5.9 Benelux GIP-1 Receptor Agonist Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia GIP-1 Receptor Agonist Revenue, 2018-2029
6.6.2 By Region – Asia GIP-1 Receptor Agonist Sales, 2018-2029
6.6.3 China GIP-1 Receptor Agonist Market Size, 2018-2029
6.6.4 Japan GIP-1 Receptor Agonist Market Size, 2018-2029
6.6.5 South Korea GIP-1 Receptor Agonist Market Size, 2018-2029
6.6.6 Southeast Asia GIP-1 Receptor Agonist Market Size, 2018-2029
6.6.7 India GIP-1 Receptor Agonist Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America GIP-1 Receptor Agonist Revenue, 2018-2029
6.7.2 By Country – South America GIP-1 Receptor Agonist Sales, 2018-2029
6.7.3 Brazil GIP-1 Receptor Agonist Market Size, 2018-2029
6.7.4 Argentina GIP-1 Receptor Agonist Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa GIP-1 Receptor Agonist Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa GIP-1 Receptor Agonist Sales, 2018-2029
6.8.3 Turkey GIP-1 Receptor Agonist Market Size, 2018-2029
6.8.4 Israel GIP-1 Receptor Agonist Market Size, 2018-2029
6.8.5 Saudi Arabia GIP-1 Receptor Agonist Market Size, 2018-2029
6.8.6 UAE GIP-1 Receptor Agonist Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 GSK
7.1.1 GSK Company Summary
7.1.2 GSK Business Overview
7.1.3 GSK GIP-1 Receptor Agonist Major Product Offerings
7.1.4 GSK GIP-1 Receptor Agonist Sales and Revenue in Global (2018-2023)
7.1.5 GSK Key News & Latest Developments
7.2 Novo Nordisk
7.2.1 Novo Nordisk Company Summary
7.2.2 Novo Nordisk Business Overview
7.2.3 Novo Nordisk GIP-1 Receptor Agonist Major Product Offerings
7.2.4 Novo Nordisk GIP-1 Receptor Agonist Sales and Revenue in Global (2018-2023)
7.2.5 Novo Nordisk Key News & Latest Developments
7.3 Eli Lilly and Company
7.3.1 Eli Lilly and Company Company Summary
7.3.2 Eli Lilly and Company Business Overview
7.3.3 Eli Lilly and Company GIP-1 Receptor Agonist Major Product Offerings
7.3.4 Eli Lilly and Company GIP-1 Receptor Agonist Sales and Revenue in Global (2018-2023)
7.3.5 Eli Lilly and Company Key News & Latest Developments
7.4 Baxter Pharmaceutical Solutions
7.4.1 Baxter Pharmaceutical Solutions Company Summary
7.4.2 Baxter Pharmaceutical Solutions Business Overview
7.4.3 Baxter Pharmaceutical Solutions GIP-1 Receptor Agonist Major Product Offerings
7.4.4 Baxter Pharmaceutical Solutions GIP-1 Receptor Agonist Sales and Revenue in Global (2018-2023)
7.4.5 Baxter Pharmaceutical Solutions Key News & Latest Developments
7.5 Sanofi
7.5.1 Sanofi Company Summary
7.5.2 Sanofi Business Overview
7.5.3 Sanofi GIP-1 Receptor Agonist Major Product Offerings
7.5.4 Sanofi GIP-1 Receptor Agonist Sales and Revenue in Global (2018-2023)
7.5.5 Sanofi Key News & Latest Developments
7.6 AstraZeneca
7.6.1 AstraZeneca Company Summary
7.6.2 AstraZeneca Business Overview
7.6.3 AstraZeneca GIP-1 Receptor Agonist Major Product Offerings
7.6.4 AstraZeneca GIP-1 Receptor Agonist Sales and Revenue in Global (2018-2023)
7.6.5 AstraZeneca Key News & Latest Developments
7.7 Shanghai Benemae Pharmaceutical Corporation
7.7.1 Shanghai Benemae Pharmaceutical Corporation Company Summary
7.7.2 Shanghai Benemae Pharmaceutical Corporation Business Overview
7.7.3 Shanghai Benemae Pharmaceutical Corporation GIP-1 Receptor Agonist Major Product Offerings
7.7.4 Shanghai Benemae Pharmaceutical Corporation GIP-1 Receptor Agonist Sales and Revenue in Global (2018-2023)
7.7.5 Shanghai Benemae Pharmaceutical Corporation Key News & Latest Developments
7.8 Sinopep Allsino Bio Pharmaceutical
7.8.1 Sinopep Allsino Bio Pharmaceutical Company Summary
7.8.2 Sinopep Allsino Bio Pharmaceutical Business Overview
7.8.3 Sinopep Allsino Bio Pharmaceutical GIP-1 Receptor Agonist Major Product Offerings
7.8.4 Sinopep Allsino Bio Pharmaceutical GIP-1 Receptor Agonist Sales and Revenue in Global (2018-2023)
7.8.5 Sinopep Allsino Bio Pharmaceutical Key News & Latest Developments
7.9 Huadong Medicine
7.9.1 Huadong Medicine Company Summary
7.9.2 Huadong Medicine Business Overview
7.9.3 Huadong Medicine GIP-1 Receptor Agonist Major Product Offerings
7.9.4 Huadong Medicine GIP-1 Receptor Agonist Sales and Revenue in Global (2018-2023)
7.9.5 Huadong Medicine Key News & Latest Developments
7.10 HANSOH PHARMA
7.10.1 HANSOH PHARMA Company Summary
7.10.2 HANSOH PHARMA Business Overview
7.10.3 HANSOH PHARMA GIP-1 Receptor Agonist Major Product Offerings
7.10.4 HANSOH PHARMA GIP-1 Receptor Agonist Sales and Revenue in Global (2018-2023)
7.10.5 HANSOH PHARMA Key News & Latest Developments
7.11 3SBio
7.11.1 3SBio Company Summary
7.11.2 3SBio Business Overview
7.11.3 3SBio GIP-1 Receptor Agonist Major Product Offerings
7.11.4 3SBio GIP-1 Receptor Agonist Sales and Revenue in Global (2018-2023)
7.11.5 3SBio Key News & Latest Developments
8 Global GIP-1 Receptor Agonist Production Capacity, Analysis
8.1 Global GIP-1 Receptor Agonist Production Capacity, 2018-2029
8.2 GIP-1 Receptor Agonist Production Capacity of Key Manufacturers in Global Market
8.3 Global GIP-1 Receptor Agonist Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 GIP-1 Receptor Agonist Supply Chain Analysis
10.1 GIP-1 Receptor Agonist Industry Value Chain
10.2 GIP-1 Receptor Agonist Upstream Market
10.3 GIP-1 Receptor Agonist Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 GIP-1 Receptor Agonist Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer